Impact of molecular diagnostics and targeted cancer therapy on patient outcomes ( MODIFY ): a retrospective study of the implementation of precision oncology
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Michaël Dang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Centre Hospitalier de Luxembourg (CHL), Luxembourg. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High‐throughput genomic analyses are being implemented in clinical practice. MODIFY is a retrospective study of the first introduction of genomic profiling and molecular tumor boards in the country of Luxembourg. The primary objective was to assess whether patients derived a clinical benefit by measuring the percentage of patients who presented a progression‐free survival (PFS) on matched therapy (PFS2) 1.3‐fold longer than PFS on previous therapy (PFS1). A total of 94 patients were included. In total, 45 patients (53.57% of patients with successful next‐generation sequencing [NGS] analysis) were found to have an actionable mutation. Of these, 11 patients received the treatment recommended by the molecular tumor board, another 12 received best‐supportive care, and 20 were treated with conventional therapy. PFS2 and PFS1 data were available for eight patients. The PFS2/PFS1 ratio was ≥ −1.3 in 62.5% ( n = 5/8; CI [30.38, 86.51]) of patients; three patients showed a partial response, and median overall survival (OS) was 7.3 months. Although the examined population was small, this study further supports evidence indicating that patients with advanced cancer benefit from molecular profiling and targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Centre Hospitalier de Luxembourg (CHL), Luxembourg.
- University of Luxembourg (Uni.lu), Luxembourg.
- Luxembourg Institute of Health (LIH), Luxembourg.
- Institut National du Cancer (INC), Luxembourg, Luxembourg.
ORCID-Profile: Michaël Dang, Nikolai Goncharenko
Zitieren
APA
Dang, M., Schritz, A., Goncharenko, N., & Berchem, G. (2025). Impact of molecular diagnostics and targeted cancer therapy on patient outcomes ( MODIFY ): a retrospective study of the implementation of precision oncology. Molecular Oncology. https://doi.org/10.1002/1878-0261.13785
Vancouver
Dang M, Schritz A, Goncharenko N, Berchem G. Impact of molecular diagnostics and targeted cancer therapy on patient outcomes ( MODIFY ): a retrospective study of the implementation of precision oncology. Molecular Oncology. 2025. doi:10.1002/1878-0261.13785
BibTeX
@article{Dang2025,
author = {Dang, Michaël and Schritz, Anna and Goncharenko, Nikolai and Berchem, Guy},
title = {Impact of molecular diagnostics and targeted cancer therapy on patient outcomes ( MODIFY ): a retrospective study of the implementation of precision oncology},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13785}
}
EUVIMED